Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 532531 | NSE Symbol : STAR | ISIN : INE939A01011 | Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
15-May-2025	22-May-2025	Final Dividend	Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2025 inter alia to consider and approve Pursuant to Regulation 29(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that a meeting of Board of Directors of the Company is scheduled to be held on Thursday May 22 2025 inter alia: 1) To consider and approve the audited financial results (standalone and consolidated) of the Company for the quarter and financial year ended March 31 2025; and 2) To consider and recommend final dividend if any on the equity shares of the Company for the financial year ended March 31 2025. Further as per the provisions of the Companys Code of Conduct for Prohibition of Insider Trading trading window for designated persons of the Company has been closed from April 1 2025 and shall open after 48 hrs post declaration of financial results of the Company. Recommendation of final dividend of Rs. 4/- per equity share of Rs. 10 each (at the rate of 40%) for FY25. Outcome of Board Meeting of the Company held on May 22, 2025 Appointment of Secretarial Auditor Update on Promoters Reclassification Request (As Per BSE Announcement Dated on 22.05.2025)
19-Mar-2025	19-Mar-2025	Demerger	Proposed de-merger of Identified Business of Arco Lab Private Limited, a wholly owned subsidiary of the Company.
24-Jan-2025	30-Jan-2025	Quarterly Results	Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2025 inter alia to consider and approve This is to inform you that meeting of Board of Directors of the Company is scheduled to be held on Thursday January 30 2025 to consider and approve the un-audited financial results (standalone and consolidated) of the Company for the quarter and nine months ended December 31 2024 amongst other matters. Further as per provisions of the Companys Code of Conduct for Prohibition of Insider Trading trading window for Designated Persons of the Company is closed from January 1 2025 and shall open after 48 hrs post declaration of un-audited financial results by the Company. Outcome of Board Meeting - Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2024. Appointment of Ms. Mukta Arora (DIN: 07225715) as Independent Director of the Company effective February 1, 2025. Change in designation of Mr. Arun Kumar (DIN: 00084845) from Executive Chairperson to Non-Executive Chairperson of the Company effective April 5, 2025. Change in Registered office of the Company (As Per BSE Announcement dated on 30.01.2025)
26-Nov-2024	26-Nov-2024	Scheme of Arrangement	Intimation of Record Date under Regulation 42 of SEBI Listing Regulations
18-Oct-2024	24-Oct-2024	Quarterly Results	Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/10/2024 inter alia to consider and approve This is to inform you that meeting of Board of Directors of the Company is scheduled to be held on Thursday October 24 2024 to consider and approve the un-audited financial results (standalone and consolidated) of the Company for the quarter and half year ended September 30 2024 amongst other matters. Further as per provisions of the Companys Code of Conduct for Prohibition of Insider Trading trading window for Designated Persons of the Company is closed from October 1 2024 and shall open after 48 hrs post declaration of financial results by the Company. The above information will also be available on the website of the Company at www.strides.com. This is for your kind information and record purposes. Outcome of Board Meeting - Unaudited Financial Results (Standalone & Consolidated) for quarter and half year ended September 30, 2024. Outcome of Board Meeting - Un-audited Financial Results (Standalone & Consolidated) for quarter and half-year ended September 30, 2024 (As Per BSE Announcement Dated on 24.10.2024)
22-Jul-2024	29-Jul-2024	Quarterly Results	Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2024 inter alia to consider and approve Announcement of Board meeting under Regulation 29 of SEBI Listing Regulations. Outcome of Board Meeting - Unaudited Financial Results (Standalone & Consolidated) for quarter ended June 30, 2024. (As Per BSE Announcement dated on 29.07.2024)
14-May-2024	22-May-2024	Final Dividend	Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2024 inter alia to consider and approve Announcement of Board Meeting under Regulation 29 of SEBI Listing Regulations Outcome of Board Meeting - May 22, 2024 Allotment of Shares Grant of Stock Options under Strides ESOP Plan Recommendation of Final Dividend for FY ended March 31, 2024 Outcome of Board Meeting - May 22, 2024 - Change in Board composition and Management Outcome of Board Meeting - May 22, 2024 - Change in Management (As Per BSE Announcement Dated on 22.05.2024)
22-Jan-2024	30-Jan-2024	Quarterly Results	Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2024 inter alia to consider and approve This is to inform you that a meeting of Board of Directors of the Company is scheduled to be held on Tuesday January 30 2024 to consider and approve the un-audited financial results (standalone and consolidated) of the Company for the quarter and nine months ended December 31 2023 amongst other matters. Further as per provisions of the Companys Code of Conduct for Prohibition of Insider Trading trading window for Designated Persons of the Company is closed and shall open after 48 hrs post declaration of financial results by the Company. Outcome of Board Meeting - Un-audited Financial Results (Standalone & Consolidated) for quarter and nine months ended December 31, 2023 Appointment of Mr. Ameet P Hariani (DIN: 00087866) as Independent Director of the Company effective February 1, 2024 (As Per BSE Announcement Dated on 30/01/2024)
02-Jan-2024	02-Jan-2024	Investments	Investment in AMP Energy
20-Oct-2023	30-Oct-2023	Quarterly Results	Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2023 inter alia to consider and approve This is to inform you that a meeting of Board of Directors of the Company is scheduled to be held on Monday October 30 2023 to consider and approve the un-audited financial results (standalone and consolidated) of the Company for the quarter and half year ended September 30 2023 amongst other matters. Further as per provisions of the Companys Code of Conduct for Prohibition of Insider Trading trading window for Designated Persons of the Company is closed and shall open after 48 hrs post declaration of financial results by the Company. This is for your kind information and record purposes. Outcome of Board Meeting - Un-audited Financial Results (Standalone & Consolidated) for quarter and half year ended September 30, 2023. (As per BSE Announcement Dated on 30/10/2023)
20-Sep-2023	25-Sep-2023	Scheme of Arrangement	Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/09/2023 inter alia to consider and approve We refer to Companys announcement of August 2 2023 as part of Q1 FY24 Earnings Presentation about our intent to combine CDMO interests of the group to become one of Indias top specialty pharmaceuticals CDMOs. We now wish to inform you that a board meeting of the Company is scheduled to be held on Monday September 25 2023 to consider the above proposal. The Company will also host a call on Monday September 25 2023 at 17:00 hrs IST to interact with the investors in connection with the above proposal. Intimation of Scheme of Arrangement, pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations) Scheme of Arrangement (As per BSE Announcement Dated on 25/09/2023)
07-Sep-2023	07-Sep-2023	Acquisitions	As part of internal restructuring within the group, Board of Directors of the Company at their meeting held on September 7, 2023 have approved acquisition of 100% shareholding in Strides Pharma Services Private Limited (SPSPL). SPSPL is currently a WOS of Arco Lab Private Limited, a WOS of the Company. Post the said acquisition, SPSPL shall be a WOS of the Company. Disclosure under Regulation 30 of SEBI Listing Regulations read with SEBI Circular of July 13, 2023 relating to the proposed transaction is enclosed.
25-Jul-2023	02-Aug-2023	Quarterly Results	Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/08/2023 inter alia to consider and approve Announcement of Board Meeting under Regulation 29 of SEBI Listing Regulations Outcome of Board Meeting - Un-audited Financial Results (Standalone & Consolidated) for quarter ended June 30, 2023. Intimation of Scheme of Amalgamation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (As Per BSE Announcement Dated on 02/08/2023)
18-May-2023	25-May-2023	Final Dividend	Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2023 inter alia to consider and approve Announcement of Board Meeting under Regulation 29 of SEBI Listing Regulations Outcome of Board Meeting - Audited Financial Results (Standalone & Consolidated) for quarter and year ended March 31, 2023 (As per BSE Announcement Dated on 25/05/2023)
17-Jan-2023	24-Jan-2023	Quarterly Results	Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/01/2023 inter alia to consider and approve This is to inform you that a meeting of Board of Directors of the Company is scheduled to be held on Tuesday January 24 2023 to consider and approve the un-audited financial results (standalone and consolidated) of the Company for the quarter and nine months ended December 31 2022 amongst other matters. Further as per provisions of the Companys Code of Conduct for Prohibition of Insider Trading trading window for Designated Persons of the Company is closed and shall open after 48 hrs post declaration of financial results by the Company. Outcome of Board Meeting - Unaudited Financial Results (Standalone & Consolidated) for the quarter and nine months ended December 31, 2022 (As Per BSE Announcement Dated on 24/01/2023)

1 2 3

LOGIN HERE

Strides Pharma Science Ltd

Board Meeting